Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6866843

Title:Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
Inventors:Habener, Joel F.; Newton Centre, MA, USA
Summary:Described herein is a method of treating diabetes mellitus or liver disease via the transfer of a nestin-positive pancreatic stem cell into a patient following the isolation of the stem cell from a pancreatic islet of a donor. The invention encompasses methods and compositions for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. The authors describe nestin as having been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are included whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Also provided are methods for the ex vivo differentiation of the pancreatic stem cells, and for their isolation, expansion and transplantation into a patient in need of such therapy, whether allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting or other cells. Further therapeutic applications include stem cell mobilization, myeloprotection, neuronal protection, wound healing, the treatment of cancer and parasitic infections, and the regulation of hematopoiesis.
Abstract:Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6866843
Application Number:US2000000731255
Date Filed:06/12/2002
Date Published:15/03/2005
Assignee:Viacell, Inc., Charlestown, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/5/2020